Company Overview of Soligenix, Inc.
Soligenix, Inc., a development stage biopharmaceutical company, engages in developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. The company focuses on two segments, BioTherapeutics and Vaccine/Biodefense. The BioTherapeutics segment develops products for orphan diseases and areas of unmet medical need, such as oral mucositis, pediatric Crohn’s disease, acute radiation enteritis, and Graft-versus-Host disease. It is developing proprietary formulations of oral beclomethasone 17.21-dipropionate for the prevention/treatment of gastrointestinal disorders characterized by severe inflamma...
29 Emmons Drive
Princeton, NJ 08540
Founded in 1987
Key Executives for Soligenix, Inc.
Total Annual Compensation: $390.0K
Acting Chief Financial Officer
Total Annual Compensation: $180.0K
Chief Scientific Officer and Senior Vice President
Total Annual Compensation: $210.0K
Compensation as of Fiscal Year 2012.
Soligenix, Inc. Key Developments
Soligenix Announces Initiation of a Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Dec 5 13
Soligenix, Inc. announced that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942 as a treatment for oral mucositis in patients undergoing chemoradiation (CRT) therapy for head and neck cancer. This Phase 2 study is a multicenter trial focused on patients with tumors of the mouth and oropharynx who often experience debilitating oral mucositis as a consequence of tumor treatment with intensity modulated radiation and chemotherapy. The primary efficacy will be assessed on the basis of the incidence and duration of both ulcerative and severe oral mucositis throughout the course of radiation treatment. Other key efficacy measures will assess patient reported outcomes, pharmacoeconomic parameters such as hospitalization and radiation-associated side effects including mouth stiffness (trismus) and dryness (xerostomia). The mechanisms of mucositis have been extensively studied and have been recently linked to the interaction of chemotherapy and/or radiation therapy with the innate defense system. Bacterial infection of the ulcerative lesions is now regarded as a secondary consequence of dysregulated local inflammation triggered by therapy-induced cell death, rather than as the primary cause of the lesions.
Soligenix, Inc. Announces Initiation of Phase 2 Clinical Trial of orBec for the Treatment of Chronic GI GVHD
Dec 2 13
Soligenix, Inc. announced that it has initiated a phase 2, randomized, double-blind, placebo-controlled study evaluating orBec(R) (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal (GI) manifestations of chronic Graft-versus-Host disease (GVHD). The study is partially funded by the National Cancer Institute (NCI) which has awarded Soligenix a Small Business Innovation Research (SBIR) grant to support the conduct of a phase 2 clinical trial. The award provides Soligenix with approximately $300,000 over a two-year period. The phase 2 study is designed as a multicenter, pilot study enrolling patients that have received allogeneic hematopoietic cell transplantation (HCT) at least 100 days earlier, have documented chronic GVHD in at least one organ outside the GI tract, and have a mucosal biopsy consistent with GI GVHD. The primary efficacy objective of the study is to estimate the proportion of subjects with chronic GVHD with GI involvement who achieve a complete response, partial response or minimal response of GI GVHD signs and symptoms when treated with orBec(R) for up to 16 weeks. Response will be assessed using a composite score based on the symptoms of satiety, nausea/vomiting, and anorexia.
Soligenix, Inc. Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2013
Nov 12 13
Soligenix, Inc. announced earnings results for the third quarter and nine months ended September 30, 2013. Revenues for the quarter ended were $0.3 million as compared to $0.9 million for the quarter ended September 30, 2012. Net loss was $6.6 million or $0.34 per share, as compared to $0.8 million or $0.07 per share, for the quarter. Included in the net loss for the quarter ended September 30, 2013 is a non-cash charge of $4.7 million due to the change in fair value of the liability related to warrants issued in the company's June 25, 2013 registered public offering.
Revenues for the nine months were $1.8 million as compared to $2.3 million for the nine months ended September 30, 2012. For the nine months ended September 30, 2013 compared to September 30, 2012, revenues decreased by $0.5 million primarily related to the timing of reimbursable costs from the company's ThermoVax(TM) thermostability technology grant focused on a novel method of rendering aluminum salt adjuvanted vaccines stable at elevated temperatures. Net loss was $11.1 million or $0.78 per share, as compared to $3.2 million or $0.29 per share for the nine months ended September 30, 2013 and 2012, respectively. The net loss for the nine months ended September 30, 2013 included a $1.5 million non-cash charge related to the exclusive worldwide collaboration with Intrexon Corporation (Intrexon) and a $5.3 million non-cash charge resulting from the change in fair value of the liability related to warrants issued in the company's June 25, 2013 registered public offering.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 18, 2013